MariMed (OTCMKTS:MRMD) versus Brainsway (NASDAQ:BWAY) Head-To-Head Review

Brainsway (NASDAQ:BWAY) and MariMed (OTCMKTS:MRMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Risk & Volatility

Brainsway has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, MariMed has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Brainsway and MariMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0	1	2	0	2.67
MariMed	0	2	0	1	2.67

Brainsway currently has a consensus price target of $30.00, indicating a potential upside of 37.74%. Given Brainsway’s higher possible upside, equities research analysts clearly believe Brainsway is more favorable than MariMed.

Earnings & Valuation

This table compares Brainsway and MariMed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$49.09 million	8.69	$2.92 million	$0.30	72.60
MariMed	$157.96 million	0.22	-$12.16 million	($0.04)	-2.19

Brainsway has higher earnings, but lower revenue than MariMed. MariMed is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Brainsway and MariMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brainsway	12.73%	9.46%	5.96%
MariMed	-11.36%	-14.67%	-4.12%

Insider & Institutional Ownership

30.1% of Brainsway shares are held by institutional investors. Comparatively, 0.2% of MariMed shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Comparatively, 19.0% of MariMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Brainsway beats MariMed on 12 of the 14 factors compared between the two stocks.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.